U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Name Type Language
IDEC-114
Preferred Name English
GALIXIMAB
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
Galiximab [WHO-DD]
Common Name English
GALIXIMAB [USAN]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD80 (ANTIGEN)) (HUMAN-MACACA IRUS MONOCLONAL IDEC-114 HEAVY CHAIN), DISULFIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-114 .LAMBDA.-CHAIN, DIMER
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD80 (ANTIGEN)) (HUMAN-MACACA IRUS MONOCLONAL IDEC-114 HEAVY CHAIN), DISULPHIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-114 .LAMBDA.-CHAIN, DIMER
Common Name English
galiximab [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C20401
Created by admin on Wed Apr 02 08:45:28 GMT 2025 , Edited by admin on Wed Apr 02 08:45:28 GMT 2025
Code System Code Type Description
ChEMBL
CHEMBL2109191
Created by admin on Wed Apr 02 08:45:28 GMT 2025 , Edited by admin on Wed Apr 02 08:45:28 GMT 2025
PRIMARY
NCI_THESAURUS
C26447
Created by admin on Wed Apr 02 08:45:28 GMT 2025 , Edited by admin on Wed Apr 02 08:45:28 GMT 2025
PRIMARY
USAN
OO-29
Created by admin on Wed Apr 02 08:45:28 GMT 2025 , Edited by admin on Wed Apr 02 08:45:28 GMT 2025
PRIMARY
WIKIPEDIA
GALIXIMAB
Created by admin on Wed Apr 02 08:45:28 GMT 2025 , Edited by admin on Wed Apr 02 08:45:28 GMT 2025
PRIMARY
CAS
357613-77-5
Created by admin on Wed Apr 02 08:45:28 GMT 2025 , Edited by admin on Wed Apr 02 08:45:28 GMT 2025
PRIMARY
INN
8339
Created by admin on Wed Apr 02 08:45:28 GMT 2025 , Edited by admin on Wed Apr 02 08:45:28 GMT 2025
PRIMARY
FDA UNII
S9OX9692ZB
Created by admin on Wed Apr 02 08:45:28 GMT 2025 , Edited by admin on Wed Apr 02 08:45:28 GMT 2025
PRIMARY
DRUG BANK
DB04901
Created by admin on Wed Apr 02 08:45:28 GMT 2025 , Edited by admin on Wed Apr 02 08:45:28 GMT 2025
PRIMARY
SMS_ID
100000175067
Created by admin on Wed Apr 02 08:45:28 GMT 2025 , Edited by admin on Wed Apr 02 08:45:28 GMT 2025
PRIMARY
ACTIVE MOIETY
GALIXIMAB
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966